Following the T1 crossing, the AβPP-independent iAβ production pathway, which is insensitive to the ACH-based drugs, would be activated and the progression of the disease would be identical to that in the placebo cohort; the manifestation of the symptoms of AD would eventually occur but with a significant delay. Here, APP is linked to Alzheimer disease.